The U.S. District Court has recently appointed Faraci Lange partner Hadley Matarazzo to the plaintiffs' steering committee handling litigation related to a blood-clot filter.
As a member of the steering committee, Matarazzo will help direct the litigation in federal court related to inferior vena cava (IVC) filters manufactured by C.R. Bard Inc., which were implanted in thousands of Americans at risk for blood clots.
C.R. Bard's Recovery filter was designed to sit inside a major vein and block blood clots from traveling to the heart or lungs. Questions have been raised whether the manufacturer was upfront about its knowledge of potentially fatal flaws. At least 27 deaths and 300 other non-fatal problems have been associated with the Bard filter over the last decade, as reported by NBC News.
Hadley Matarazzo, who oversees Faraci Lange's defective drug and medical device practice, has extensive experience handling complex litigation, including serving in other court-appointed leadership positions in multi-district litigation in federal court and multi-county litigation in New Jersey. She focuses her legal practice on medical device and pharmaceutical liability, toxic torts, medical malpractice, consumer protection, and catastrophic personal injury.